Literature DB >> 21054348

Prior hospitalization for stroke, diabetes, myocardial infarction, and subsequent risk of unprovoked seizures.

Cecilia Adelöw1, Tomas Andersson, Anders Ahlbom, Torbjörn Tomson.   

Abstract

PURPOSE: To study diabetes, acute myocardial infarction, and stroke as risk factors for unprovoked seizures in a population-based cohort with incident cases of epilepsy.
METHODS: In this nested case-control study, the cases were 933 patients with newly diagnosed unprovoked seizures from the Stockholm Incidence Registry of Epilepsy. Controls, in total 6,039--matched for gender, year of diagnosis, and catchment area--were randomly selected from the register of the Stockholm County population. A history of diabetes, myocardial infarction, and stroke preceding the date of onset of seizure was determined by search of the Swedish Hospital Discharge Registry. Odds ratios (ORs) were calculated to assess the risk of developing unprovoked seizures after hospital admission for any of these diagnoses.
RESULTS: The age-adjusted OR (95% confidence interval, 95% CI) for unprovoked seizures after a discharge diagnosis of diabetes was 1.9 (95% CI 1.4-2.8) and after acute myocardial infarction 1.7 (95% CI 1.0-2.9). The OR was 9.4 (95% CI 6.7-13.1) after cerebral infarction, 7.2 (95% CI 3.9-13.6) after intracerebral hemorrhage, 7.2 (95% CI 2.9-18.1) after subarachnoid hemorrhage, and 3.2 (95% CI 1.9-5.5) after transient ischemic attack. The population attributable risk percent (PAR%) was <2% for each of the diagnoses except for cerebral infarction, for which the PAR% was 9%. Taken together the studied diagnoses accounted for 15% of the incident cases of unprovoked seizures. DISCUSSION: As previously known, the risk for unprovoked seizures and epilepsy after a cerebral infarction was highest the first year after the infarction. This risk remained substantial >7 years after a diagnosis of cerebral infarction. Wiley Periodicals, Inc.
© 2010 International League Against Epilepsy.

Entities:  

Mesh:

Year:  2010        PMID: 21054348     DOI: 10.1111/j.1528-1167.2010.02757.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  8 in total

1.  Late-onset epilepsy and 25-year cognitive change: The Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Emily L Johnson; Gregory L Krauss; Keenan A Walker; Jason Brandt; Anna Kucharska-Newton; Thomas H Mosley; Sevil Yasar; Rebecca F Gottesman
Journal:  Epilepsia       Date:  2020-07-24       Impact factor: 5.864

Review 2.  Delirium and sedation in the ICU.

Authors:  Jennifer A Frontera
Journal:  Neurocrit Care       Date:  2011-06       Impact factor: 3.210

3.  Adults with an epilepsy history, notably those 45-64 years old or at the lowest income levels, more often report heart disease than adults without an epilepsy history.

Authors:  Matthew Zack; Cecily Luncheon
Journal:  Epilepsy Behav       Date:  2018-06-13       Impact factor: 2.937

4.  Seven questions about stroke and epilepsy.

Authors:  Thomas P Bleck
Journal:  Epilepsy Curr       Date:  2012-11       Impact factor: 7.500

5.  New differentially expressed genes and differential DNA methylation underlying refractory epilepsy.

Authors:  Xi Liu; Shu Ou; Tao Xu; Shiyong Liu; Jinxian Yuan; Hao Huang; Lu Qin; Hui Yang; Lifen Chen; Xinjie Tan; Yangmei Chen
Journal:  Oncotarget       Date:  2016-12-27

6.  Predictors of Seizure Recurrence after Acute Symptomatic Seizures in Ischemic Stroke Patients.

Authors:  Pravin George; Vineet Punia; Prashant A Natteru; Stephen Hantus; Christopher Newey
Journal:  Neurosci J       Date:  2019-10-31

7.  Incidence, predictors, and outcomes of post-thrombectomy seizures in the extended time window.

Authors:  Shruti Agashe; Destiny Hooper; Tariq Nisar; David McCane; Jason Lee; Ken Chyuan Ling; Farhaan S Vahidy; David Chiu; Rajan R Gadhia
Journal:  Epilepsy Behav Rep       Date:  2021-01-07

Review 8.  The New Antiepileptic Drugs: Their Neuropharmacology and Clinical Indications.

Authors:  Ryosuke Hanaya; Kazunori Arita
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-03-02       Impact factor: 1.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.